Document is current
Any future updates will be listed below
-
Authors
Rueda-Lara, Maria https://orcid.org/0009-0005-5683-3364
Barrera, Ingrid
Komanduri, Krishna V.
Pereira, Denise https://orcid.org/0000-0002-1992-7899
Lekakis, Lazaros
Wang, Trent Peng https://orcid.org/0000-0001-5685-7204
Jimenez, Antonio M. https://orcid.org/0000-0003-2817-6836
Beitinjaneh, Amer
Holtzman, Noa G.
Green, Damian J.
Goodman, Mark
Benjamin, Cara L.
Spiegel, Jay
Lehardy, Emaan Nor https://orcid.org/0000-0002-8575-712X
Antoni, Michael H. https://orcid.org/0000-0002-3971-0873
Goldstein, Hillary
Harvey, Philip D.
Wright, Brittany J. https://orcid.org/0000-0001-8911-1740
- License Information
-
More Information
Article History
Received: 17 February 2025
Revised: 30 April 2025
Accepted: 20 May 2025
First Online: 2 June 2025
Competing interests
: Dr Harvey has received consulting fees or travel reimbursements from Alkermes, BMS (Karuna Therapeutics), Boehringer Ingelheim, Merck Pharma, and Minerva Neurosciences. Dr. Antoni is a consultant for Blue Note Therapeutics, is the co-inventor of the CBSM intervention (filed as UMIP-483 by the University of Miami), and receives small royalties for treatment manuals associated with CBSM from Oxford Press and APA Press. He also receives royalties from Pearson for a personality test that he co-authored. Dr. Damian J Green has served as an advisor and has received research funding and royalties from Juno Therapeutics, a Bristol-Myers Squibb company; has served as an advisor and received research funding from Seattle Genetics, Janssen Biotech and Bristol-Myers Squibb; has served as an advisor for GlaxoSmithKline, Celgene, Ensoma, and Legend Biotech; has NIH funding under: R01 CA1076287, P01 CA078902, R01 CA289752, P01 CA018029 and has received research funding from SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. All other authors report no conflict of interest. The authors confirm that they have met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.
: All methods were performed in accordance with relevant guidelines and regulations. The study was approved by the University of Miami Institutional Review Board, IRB#20140779. It was determined to be an exempt study. Patients were not consented as data was collected as part of routine care.
